{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:47:52Z","timestamp":1792226872893,"version":"4.4.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Musculoskeletal complications are the main manifestations in adults with X-linked hypophosphatemia (XLH). Enthesopathy significantly impairs quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify the risk factors associated with the development and progression of spinal enthesopathies in adults with XLH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>We conducted a retrospective study in the French Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Adults XLH patients with 2 EOS\u00ae imaging performed at least 2 years apart at the same center between June 2011 and March 2022. The progression of enthesopathies was defined as a new enthesopathy at least 1 intervertebral level in patients with or without presence of enthesopathy at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Demographic, treatment, PHEX mutation with the progression of enthesopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-one patients (66.7% of women, mean age 42.1 \u00b1 13.4 years) underwent 2 EOS imaging with an average interval of 5.7 (\u00b1 2.31) years.<\/jats:p>\n                    <jats:p>Progression of spinal enthesopathies was observed in 27 (52.9%) patients. In univariate analysis, patients with a progression of spinal enthesopathies were significantly older (P &amp;lt; .0005), were significantly older at treatment initiation (P = .02), presented with dental complications (P = .03), received less frequently treatment during childhood with phosphate and\/or vitamin D analogs (P = .06), and presented more frequently with hip osteoarthritis (P = .002) at baseline. In multivariate analysis, none of these factors was associated with a progression of spinal enthesopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms the high proportion of patients with a progression of spinal enthesopathies. Age seems to be the main factor associated with progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad383","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T13:16:39Z","timestamp":1687871799000},"page":"e1524-e1531","source":"Crossref","is-referenced-by-count":7,"title":["Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-9503","authenticated-orcid":false,"given":"Julia","family":"Herrou","sequence":"first","affiliation":[{"name":"Department of Rheumatology, INSERM UMR 1153, Universit\u00e9 de Paris-Cit\u00e9, APHP Centre, Cochin Hospital , 75014 Paris , France"},{"name":"Department of Rheumatology, APHP Centre, Cochin Hospital , 75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Fechtenbaum","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, APHP Centre, Cochin Hospital , 75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders , Paris , France"},{"name":"Department of Endocrinology and Diabetes for Children, APHP, Bic\u00eatre Paris Saclay Hospital , 94270 Le Kremlin Bic\u00eatre , France"},{"name":"APHP, Plateforme d\u2019expertise Paris Saclay maladies rares, Bic\u00eatre Paris Saclay Hospital , 94270 Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders , Paris , France"},{"name":"Universit\u00e9 Paris-Saclay, INSERM UMR-S 1185, Physiologie et Physiopathologie Endocriniennes , 94270 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, INSERM UMR 1153, Universit\u00e9 de Paris-Cit\u00e9, APHP Centre, Cochin Hospital , 75014 Paris , France"},{"name":"Department of Rheumatology, APHP Centre, Cochin Hospital , 75014 Paris , France"},{"name":"Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-002X","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[{"name":"Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders , Paris , France"},{"name":"Department of Endocrinology and Diabetes for Children, APHP, Bic\u00eatre Paris Saclay Hospital , 94270 Le Kremlin Bic\u00eatre , France"},{"name":"APHP, Plateforme d\u2019expertise Paris Saclay maladies rares, Bic\u00eatre Paris Saclay Hospital , 94270 Le Kremlin Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-2601","authenticated-orcid":false,"given":"Karine","family":"Briot","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, INSERM UMR 1153, Universit\u00e9 de Paris-Cit\u00e9, APHP Centre, Cochin Hospital , 75014 Paris , France"},{"name":"Department of Rheumatology, APHP Centre, Cochin Hospital , 75014 Paris , France"},{"name":"Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"2","key":"2023111712404058600_dgad383-B1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023111712404058600_dgad383-B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00439-009-0631-z","article-title":"PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets","volume":"125","author":"Gaucher","year":"2009","journal-title":"Hum Genet"},{"issue":"1","key":"2023111712404058600_dgad383-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1098-1004(200007)16:1<1::AID-HUMU1>3.0.CO;2-J","article-title":"PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia","volume":"16","author":"Sabbagh","year":"2000","journal-title":"Hum Mutat"},{"issue":"1","key":"2023111712404058600_dgad383-B4","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00016.2003","article-title":"FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization","volume":"285","author":"Quarles","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"2023111712404058600_dgad383-B5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium","volume":"11","year":"1995","journal-title":"Nat Genet"},{"key":"2023111712404058600_dgad383-B6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bone.2015.05.040","article-title":"Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets","volume":"79","author":"Capelli","year":"2015","journal-title":"Bone"},{"issue":"11","key":"2023111712404058600_dgad383-B7","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1210\/jc.2010-0589","article-title":"Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status","volume":"95","author":"Carpenter","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023111712404058600_dgad383-B8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"3","key":"2023111712404058600_dgad383-B9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023111712404058600_dgad383-B10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2023111712404058600_dgad383-B11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets in adults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2023111712404058600_dgad383-B12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-009-9270-6","article-title":"Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice","volume":"85","author":"Liang","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2023111712404058600_dgad383-B13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"issue":"3","key":"2023111712404058600_dgad383-B14","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023111712404058600_dgad383-B15","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1210\/clinem\/dgab580","article-title":"Prevalence of enthesopathies in adults with X-linked hypophosphatemia: analysis of risk factors","volume":"107","author":"Herrou","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023111712404058600_dgad383-B16","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023111712404058600_dgad383-B17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/clinem\/dgac732","article-title":"Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH","volume":"108","author":"Kato","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2023111712404058600_dgad383-B18"},{"issue":"8","key":"2023111712404058600_dgad383-B19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"2","key":"2023111712404058600_dgad383-B20","first-page":"287","article-title":"[A new 2D and 3D imaging approach to musculoskeletal physiology and pathology with low-dose radiation and the standing position: the EOS system","volume":"189","author":"Dubousset","year":"2005","journal-title":"Bull Acad Natl Med"},{"issue":"3","key":"2023111712404058600_dgad383-B21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/key128","article-title":"Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis","volume":"58","author":"Heijde","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"2023111712404058600_dgad383-B22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2023111712404058600_dgad383-B23","doi-asserted-by":"crossref","first-page":"e3682","DOI":"10.1210\/clinem\/dgab282","article-title":"Incidence of complications in 25 adult patients with X-linked hypophosphatemia","volume":"106","author":"Kato","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023111712404058600_dgad383-B24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00223-022-00989-7","article-title":"The enthesopathy of XLH is a mechanical adaptation to osteomalacia: biomechanical evidence from hyp mice","volume":"111","author":"Macica","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"2023111712404058600_dgad383-B25","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3389\/fcell.2020.00854","article-title":"Development of enthesopathies and joint structural damage in a murine model of X-linked hypophosphatemia","volume":"8:","author":"Faraji-Bell\u00e9e","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2023111712404058600_dgad383-B26","doi-asserted-by":"crossref","first-page":"591417","DOI":"10.3389\/fcell.2020.591417","article-title":"Impact of early conventional treatment on adult bone and joints in a murine model of X-linked hypophosphatemia","volume":"8","author":"Cauliez","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"2023111712404058600_dgad383-B27","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2023111712404058600_dgad383-B28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"2023111712404058600_dgad383-B29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2023111712404058600_dgad383-B30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122693","article-title":"Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-\u03b1 blocking therapy: a prospective longitudinal observational cohort study","volume":"10","author":"Maas","year":"2015","journal-title":"PLoS One"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad383\/50916291\/dgad383.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/e1524\/53480897\/dgad383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/e1524\/53480897\/dgad383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T08:42:45Z","timestamp":1700210565000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/12\/e1524\/7214054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad383","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,6,30]]}}}